Profile: OncoSec Medical Inc (ONCS.PH)
8 Aug 2019
OncoSec Medical Incorporated, incorporated on February 8, 2008, is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer.
The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, the Company is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer.
The Company's ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses. The Company's product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, Interleukin 12 (IL-12), which is delivered into the tumor through in vivo electroporation.
OncoSec Medical Inc
24 N Main St
PENNINGTON NJ 08534-2218